The Dynamin Like 120 kDa Protein Mitochondrial pipeline drugs market research report outlays comprehensive information on the Dynamin Like 120 kDa Protein Mitochondrial targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Dynamin Like 120 kDa Protein Mitochondrial pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology which include the indications Ophthalmology, and Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy). It also reviews key players involved in Dynamin Like 120 kDa Protein Mitochondrial targeted therapeutics development with respective active and dormant or discontinued products.
The Dynamin Like 120 kDa Protein Mitochondrial pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, IND/ CTA Filed, and Preclinical stages are 1, 1, and 3 respectively.
Dynamin Like 120 kDa Protein Mitochondrial overview
The Dynamin-Like 120 kDa Protein Mitochondrial, commonly known as OPA1 (Optic Atrophy 1), is crucial for maintaining normal mitochondrial morphology by regulating the balance between mitochondrial fusion and fission. Optimal activity in promoting mitochondrial fusion requires the coexpression of isoform 1 with shorter alternative products. OPA1 binds to lipid membranes rich in negatively charged phospholipids, such as cardiolipin, facilitating membrane tubulation. It also plays a role in reshaping cristae and facilitating the release of cytochrome c during apoptosis. Mutations in the OPA1 gene are associated with specific genetic disorders, including autosomal dominant optic atrophy (ADOA), a condition that primarily impacts the optic nerves and can result in vision impairment.
For a complete picture of Dynamin Like 120 kDa Protein Mitochondrial’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
